[go: up one dir, main page]

BR0212151A - Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas - Google Patents

Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas

Info

Publication number
BR0212151A
BR0212151A BR0212151-4A BR0212151A BR0212151A BR 0212151 A BR0212151 A BR 0212151A BR 0212151 A BR0212151 A BR 0212151A BR 0212151 A BR0212151 A BR 0212151A
Authority
BR
Brazil
Prior art keywords
trauma
nerve damage
compounds
conditions resulting
treat conditions
Prior art date
Application number
BR0212151-4A
Other languages
English (en)
Inventor
Mark R Hellberg
Iok-Hou Pang
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0212151A publication Critical patent/BR0212151A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/08Ethers or acetals acyclic, e.g. paraformaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE COMPOSTOS PARA TRATAR CONDIçõES RESULTANTES DE DANO AO NERVO CORNEANO APóS CIRURGIAS DE LASIK E OUTRAS OCULARES OU TRAUMAS". A presente invenção refere-se métodos para o tratamento de condições resultantes de dano ao nervo corneano após cirurgias de LASIK e outras oculares ou trauma.
BR0212151-4A 2001-08-29 2002-07-23 Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas BR0212151A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29
PCT/US2002/023871 WO2003020281A1 (en) 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Publications (1)

Publication Number Publication Date
BR0212151A true BR0212151A (pt) 2004-08-24

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212151-4A BR0212151A (pt) 2001-08-29 2002-07-23 Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas

Country Status (10)

Country Link
EP (1) EP1420791A4 (pt)
JP (1) JP2005502678A (pt)
CN (1) CN1549718A (pt)
AR (1) AR036194A1 (pt)
BR (1) BR0212151A (pt)
CA (1) CA2455896A1 (pt)
MX (1) MXPA04001255A (pt)
PL (1) PL368565A1 (pt)
WO (1) WO2003020281A1 (pt)
ZA (1) ZA200400837B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE525111T1 (de) * 2003-04-18 2011-10-15 Senju Pharma Co 2-chloro-6,7-dimethoxy-n-5 ä5-(1)h- indazolylüquinazolin-4-amin, n-(1-benzyl-4- piperidinyl)-1h-indazol-5-amin dihydrochlorid, 4- ä2-(2,3,4,5,6-
ES2234428B1 (es) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
KR20070036031A (ko) * 2004-04-23 2007-04-02 센주 세이야꾸 가부시키가이샤 Pacap 및 이의 유도체를 함유하는 각막 신경세포 형성촉진제
WO2005118582A1 (ja) 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
EP2266559A1 (en) 2005-03-15 2010-12-29 Ono Pharmaceutical Co., Ltd. Therapeutic agent for ophthalmic disease
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
WO2001085152A2 (en) * 2000-05-10 2001-11-15 Alcon, Inc. R-eliprodil for treating glaucoma

Also Published As

Publication number Publication date
EP1420791A1 (en) 2004-05-26
CA2455896A1 (en) 2003-03-13
ZA200400837B (en) 2005-02-02
WO2003020281A1 (en) 2003-03-13
EP1420791A4 (en) 2004-09-15
PL368565A1 (en) 2005-04-04
JP2005502678A (ja) 2005-01-27
CN1549718A (zh) 2004-11-24
AR036194A1 (es) 2004-08-18
MXPA04001255A (es) 2004-05-27

Similar Documents

Publication Publication Date Title
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE60022544D1 (de) Behandlung von augenerkrankungen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
HK1038694A1 (zh) 治疗眼、耳、鼻病症的抗生素合成剂
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
BR9907715A (pt) Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose
BR0212151A (pt) Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
DE602005008935D1 (de) Statine zur behandlung von okularer hypertonie und glaukom
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
BR0017340A (pt) Tratamento de trauma e outras indicações
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
DE69525631D1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
ATE215824T1 (de) Mittel zur verminderung des augeninnendrucks
AU4397197A (en) Subepithelial turbidity inhibitor
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
BR0215752A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
RU95107870A (ru) Способ лечения послеоперационной цилиохориоидальной отслойки
BR0015486A (pt) Ligandos de neurofilina para tratamento de condições oculares

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired